KIDRON NADAV 4

What Happened
Nadav Kidron, President, CEO and a director of Oramed Pharmaceuticals (ORMP), disposed of 44,818 shares on 2026-03-30 to satisfy tax withholding obligations related to vested Restricted Stock Units (RSUs). The shares were valued at $3.31 per share, for a total of roughly $148,348.

Key Details

• Transaction date: 2026-03-30; filing date (Form 4): 2026-03-31 (filed within required reporting window).
• Disposed shares: 44,818 at $3.31 per share; total value ≈ $148,348.
• Transaction code: F — shares used to satisfy tax withholding on RSU vesting.
• Footnote: The $3.31/share value equals the issuer’s closing price on the day before vesting.
• Shares owned after transaction: Not disclosed in the supplied filing.

Context
This was a routine stock surrender to cover tax liabilities from RSU vesting (a common corporate practice) rather than an open-market sale that signals a change in investment view. Such tax-withholding dispositions are generally considered administrative and do not necessarily reflect the insider’s sentiment about the company.